Navigation Links
Warner Chilcott Announces Receipt of Paragraph IV Certification Notices
Date:8/3/2009

ther similar expressions are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties. The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness; competitive factors in the industry in which we operate (including the approval and introduction of generic or branded products that compete with our products); our ability to protect our intellectual property; a delay in qualifying our manufacturing facility to produce our products or production or regulatory problems with either third party manufacturers upon whom we may rely for some of our products or our own manufacturing facilities; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our outstanding litigation or an increase in the number of litigation matters to which we are subject; government regulation affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new prod
'/>"/>
SOURCE Warner Chilcott Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Warner Chilcott Announces Earnings Release Date and Conference Call For Second Quarter 2009 Financial Results
2. Warner Chilcott to Hold 2009 Annual General Meeting of Shareholders and Special Court-Ordered Meeting of Shareholders
3. Warner Chilcott to Present at Wachovias 19th Annual Mid-Year Equity Conference
4. Senators Webb and Warner Vote to Protect Americas Kids From Tobacco
5. Warner Chilcott to Present at the Goldman Sachs 30th Annual Healthcare Conference
6. Warner Chilcott Announces FDA Acceptance of NDA Submission for Low Dose Oral Contraceptive
7. Warner Chilcott Reports Operating Results for the Quarter Ended March 31, 2009 and Updates 2009 Full Year Guidance
8. Warner Chilcott Proposes Redomestication From Bermuda to Ireland
9. Warner Chilcott to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
10. Warner Chilcott Files New Lawsuit for Infringement of DORYX(R) Patent
11. HBO, Warner Bros. Employee Initiatives and the Alzheimers Association, California Southland Chapter Present a Free, Public, Advance Screening of THE ALZHEIMERS PROJECT: Caregivers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... Girl Scouts of Historic Georgia and Peach State ... Girl Scout "Be a Friend First" program. Representatives from Peach State Health Plan presented ... State Health Plan and our parent company, Centene Corporation, are dedicated to raising anti-bullying ...
(Date:7/31/2015)... IL (PRWEB) , ... July 31, 2015 , ... The ... Boston, when Major League Baseball and the Boston Red Sox honor Ice Bucket co-founders ... the challenge. MLB is donating $100,000 to further collaborative efforts among the ALS organizations ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... for the Northern District of Ohio, Western Division (Case No. 3:15-cv-00397) involving the ... 3:15-cv-00397), the women experienced spontaneous migration of their Implanon® implants, inability to locate ...
(Date:7/31/2015)... ... ... The alarm was ringing. Hugh Chatfield, survivor of a severe 1987 brain injury, almost slept ... equipment was set up to depict the newly poured concrete. With a clear view of ... speaks for itself. Chatfield is also a highly praised safety and drug education speaker/comedian. , ...
(Date:7/31/2015)... ... 2015 , ... Patients with higher levels of a key protein are at ... Communications and led by researchers from the Icahn School of Medicine at Mount Sinai. ... led to greater production of the related RNT1 protein, which caused kidney cells to ...
Breaking Medicine News(10 mins):Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 3Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 4Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3
... broke his silence for the first time. Since his parents broke ... problem of substance abuse. ,He revealed that he was ... He was being treated for a number of illnesses as a ... the name of the drug that he had been using. ...
... today issued the "Critical Path Opportunities for Generic Drugs" ... impede the development of generic versions of commonly used ... Critical Path Initiative, established in 2004 to discern what ... device along the critical path from discovery, or proof ...
... but a Dartmouth discovery that a cousin of niacin prolongs ... ,The research, reported in the May 4 issue ... yeast cells, much like calorie restriction does in animals. It ... ,Radical calorie reduction can extend life. Dieting or ...
... women who took an epilepsy drug during their pregnancy are ... In question is the drug valproate (already at the ... has damaged children). Valproate seems to double the chance that ... ,Around 140 British families claim that their children are ...
... research published in the journal Proceedings of the National ... produce// an antibiotic which inhibits the work of an ... from attack. ,Although such so-called gene-for-gene interactions ... examples of a single gene in a pathogen targeting ...
... an agency of the New York state government has lashed ... Hospital// as a shameful "chamber of filth, decay, indifference and ... Union, the agency has filed a suit in the federal ... where patients are subjected to overcrowded conditions, physical abuse and ...
Cached Medicine News:Health News:Cousins Recovering from His Substance Abuse Problem 2Health News:New Critical Path Report Highlights Research Needed to Foster Generic Drug Development 2Health News:Vitamin Extends Life in Yeast, Dartmouth Medical School Researchers Find 2Health News:Vitamin Extends Life in Yeast, Dartmouth Medical School Researchers Find 3Health News:Anti-Epileptic Drug Intake May Result In Children With Mental Retardation 2Health News:Scientists Discover Rare ‘gene-for-gene’ Interaction That Helps Bacteria Kill Their Ho 2Health News:Suit Filed Against Horrors of Psychiatric Ward in New York Hospital 2
(Date:7/31/2015)... , July 31, 2015  Xencor, Inc. (NASDAQ: ... monoclonal antibodies for the treatment of autoimmune diseases, asthma ... of Yujiro S. Hata to its board ... in business and corporate development is a tremendous asset ... president and chief executive officer of Xencor. "Xencor faces ...
(Date:7/31/2015)... India , July 31, 2015 ... CRM solutions for video, data and cloud computing ... with a leading pharma giant for Internet of ... different IoT applications offered on subscription model. ... Pharma giant is striving for business innovations ...
(Date:7/30/2015)... Mettler-Toledo International Inc. (NYSE: MTD ) ... are the highlights: , Sales in local ... prior year. Reported sales decreased 4% as currency reduced ... Net earnings per diluted share as reported (EPS) were ... EPS was $2.80 , an increase of 9% ...
Breaking Medicine Technology:Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14
... 26, 2011 Covance Inc. (NYSE: CVD ... ended December 31, 2010 of $0.45 per diluted share. ... share in costs from the previously-announced fourth quarter restructuring ... diluted share from favorable income tax resolutions in the ...
... CHENGDU, China, Jan. 26, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin ... ), a pharmaceutical company that specializes in the ... and other pharmaceuticals announced the completion of the ... Xinjin Industrial Development Area, near Chengdu, China. ...
Cached Medicine Technology:Covance Reports Fourth Quarter Revenue of $492 Million, GAAP EPS of $0.45, and Pro Forma EPS of $0.56 2Covance Reports Fourth Quarter Revenue of $492 Million, GAAP EPS of $0.45, and Pro Forma EPS of $0.56 3Covance Reports Fourth Quarter Revenue of $492 Million, GAAP EPS of $0.45, and Pro Forma EPS of $0.56 4Covance Reports Fourth Quarter Revenue of $492 Million, GAAP EPS of $0.45, and Pro Forma EPS of $0.56 5Covance Reports Fourth Quarter Revenue of $492 Million, GAAP EPS of $0.45, and Pro Forma EPS of $0.56 6Covance Reports Fourth Quarter Revenue of $492 Million, GAAP EPS of $0.45, and Pro Forma EPS of $0.56 7Covance Reports Fourth Quarter Revenue of $492 Million, GAAP EPS of $0.45, and Pro Forma EPS of $0.56 8Covance Reports Fourth Quarter Revenue of $492 Million, GAAP EPS of $0.45, and Pro Forma EPS of $0.56 9Covance Reports Fourth Quarter Revenue of $492 Million, GAAP EPS of $0.45, and Pro Forma EPS of $0.56 10Covance Reports Fourth Quarter Revenue of $492 Million, GAAP EPS of $0.45, and Pro Forma EPS of $0.56 11Covance Reports Fourth Quarter Revenue of $492 Million, GAAP EPS of $0.45, and Pro Forma EPS of $0.56 12Covance Reports Fourth Quarter Revenue of $492 Million, GAAP EPS of $0.45, and Pro Forma EPS of $0.56 13Jiangchuan Macrolide Facility Construction Completed 2Jiangchuan Macrolide Facility Construction Completed 3
Freer elevator, double end, 7 1/4", S/B....
... The Surgifoam* absorbable gelatin sponge, U.S.P. ... gelatin absorbable sponge intended for hemostatic ... surface. The sponge is off-white and ... speed to hemostasis, highly favorable surgeon ...
... absorbable gelatin sponge, U.S.P. is a ... sponge intended for hemostatic use by ... sponge is off-white and porous in ... hemostasis, highly favorable surgeon preference ratings ...
16 mm diameter curved probes with suture eyes just back of blunt ends. Stainless steel. Round knurled handle with polished finish. Overall length: 5.7 inches....
Medicine Products: